open access

Vol 25, No 5 (2020)
Reviews
Published online: 2020-09-01
Submitted: 2020-05-24
Get Citation

Functional response difference between diabetic/normal cancerous patients to inflammatory cytokines and oxidative stresses after radiotherapy

Parinaz Mehnati, Behzad Baradaran, Fatemeh Vahidian, Sousan Nadiriazam
DOI: 10.1016/j.rpor.2020.06.008
·
Rep Pract Oncol Radiother 2020;25(5):730-737.

open access

Vol 25, No 5 (2020)
Reviews
Published online: 2020-09-01
Submitted: 2020-05-24

Abstract

Diabetes, which is considered as a chronic metabolic disorder leads to an increase in inflammatory cytokines and oxidative stresses. Studies have shown several functional differences in the oxidative stress and inflammatory cytokines responses in diabetic/normal cancerous patients candidate for radiotherapy. Also, radiotherapy as a cancer treatment modality is known as a carcinogen due to oxidative damage via generation of reactive oxygen metabolites and also causing inflammation of the tissue by increasing the inflammatory cytokines. Therefore, the consequence of diabetes on oxidative stress and increased inflammatory factors and synergistic effects of radiotherapy on these factors cause complications in diabetics undergoing radiotherapy. It is considered as one of the most interesting objectives to control inflammation and oxidative stress in these patients. This review aims to concentrate on the influence of factors such as MPO, MDA, IL-1β, and TNF-α in diabetic patients by emphasizing the effects related to radiation-induced toxicity and inflammation by proposing therapeutic approaches which could be helpful in reduction of the complications.

Abstract

Diabetes, which is considered as a chronic metabolic disorder leads to an increase in inflammatory cytokines and oxidative stresses. Studies have shown several functional differences in the oxidative stress and inflammatory cytokines responses in diabetic/normal cancerous patients candidate for radiotherapy. Also, radiotherapy as a cancer treatment modality is known as a carcinogen due to oxidative damage via generation of reactive oxygen metabolites and also causing inflammation of the tissue by increasing the inflammatory cytokines. Therefore, the consequence of diabetes on oxidative stress and increased inflammatory factors and synergistic effects of radiotherapy on these factors cause complications in diabetics undergoing radiotherapy. It is considered as one of the most interesting objectives to control inflammation and oxidative stress in these patients. This review aims to concentrate on the influence of factors such as MPO, MDA, IL-1β, and TNF-α in diabetic patients by emphasizing the effects related to radiation-induced toxicity and inflammation by proposing therapeutic approaches which could be helpful in reduction of the complications.

Get Citation

Keywords

Diabetes; Inflammation; Radiotherapy; Oxidative stress; Immune system

About this article
Title

Functional response difference between diabetic/normal cancerous patients to inflammatory cytokines and oxidative stresses after radiotherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 5 (2020)

Pages

730-737

Published online

2020-09-01

DOI

10.1016/j.rpor.2020.06.008

Bibliographic record

Rep Pract Oncol Radiother 2020;25(5):730-737.

Keywords

Diabetes
Inflammation
Radiotherapy
Oxidative stress
Immune system

Authors

Parinaz Mehnati
Behzad Baradaran
Fatemeh Vahidian
Sousan Nadiriazam

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl